wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34106870-260AD84B-4794-49E2-8EDB-354D06EEFAF0
Q34106870-260AD84B-4794-49E2-8EDB-354D06EEFAF0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34106870-260AD84B-4794-49E2-8EDB-354D06EEFAF0
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
P2860
Q34106870-260AD84B-4794-49E2-8EDB-354D06EEFAF0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34106870-260AD84B-4794-49E2-8EDB-354D06EEFAF0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
32bd91c064002247cb1309e5ae1b36bffb204add
P2860
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.